產(chǎn)品名稱：Thrombosis Profile ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號：DE7600 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說明： Special remarks: The Thrombosis Profile assay is a quantitative enzyme immunoassay (EIA) intended to screen for the presence of IgG and IgM class autoantibodies against b2-Glycoprotein I, Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic acid in human serum or plasma as an aid in the diagnosis of an increased risk of thrombosis in patients with Systemic Lupus Erythematosus (SLE) or lupus-like disorders. The first study of antiphospholipid antibodies began in 1906, when Wasserman intro-duced a serological test for Syphilis. In 1942, the active component was found to be a phospholipid, which was designated Cardiolipin. In the 1950s it became clear that a number of people had positive tests for syphilis without any evidence of the disease. This phenomenon was refer-red to as the biological false positive serological test for syphilis. A high prevalence of autoimmune disorders, including systemic lupus erythematosus (SLE) and Sjögrens Syndrome occurred in this group of patients. The presence of circulating anti-coagulants in patients with SLE was first documented in 1952 and was associated with increased risk of paradoxical Thrombosis in 1963. The term Lupus anticoagulant (LA) was first used in 1972, is clearly a misnomer, because LA is more frequently encountered in patients without lupus and is associated with thrombosis rather than abnormal bleeding. During the last years it became clear that the optimal binding of anti phospholipid antibodies is de-pending on a co-factor termed b2-Glycoprotein I (apolipoprotein H) (GPI). GPI is a 50 kDa b2-globulin occurring in plasma at a level of 200 µg/ml. It has been found that b2-Glycoprotein I (b2GPI) inhibits the intrinsic coagulation pathway and, therefore, it is involved in the regulation of blood coagulation. ß2GPI is associated in vivo with negatively-charged substances, e.g. anionic phospholipids, heparin and lipo-proteins. The phospholipid binding region is located on its fifth domain. Under the acronym "aPL" (anti-Phospholipid antibodies) antibodies against negatively charged phospholipids, such as CL (Cardiolipin), LA (Lupus Anticoagulant), PS (Phosphatidylserine), PI (Phosphatidylinositol) and PA (Phosphatidic Acid) are summarised. Of these, CL is the phospholipid most commonly used as antigen to test for aPL by ELISA. Some antisera which bind cardiolipincoated ELISA plates can also bind plates coated with other negatively charged phospholipids, such as phosphatidylserine (PS) and phosphatidic acid (PA). Some investigators have suggested that the use of PS in place of cardiolipin in ELISA tests enables more specific diagnosis. These antigens are less commonly used and their additional use can improve the clinical sensitivity in patient samples with sus-pected APS (Anti-Phospholipid-Syn-drome), but at this time it seems that they can't replace the measurement of autoantibodies against Cardiolipin. To find out more about the different clinical relevance of the different phospholipid autoantibodies, we designed the Thrombosis Profile test system. 上海玉博生物技術有限公司在為生命科學領域提供豐富的產(chǎn)品與信息資源方面處于國內(nèi)**地位，公司提供的產(chǎn)品涵蓋了二十多個國家近五十萬種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長和更新，公司提供的產(chǎn)品能夠使生命科學工作者加快對生物化學，分子生物學，細胞生物學以及蛋白質(zhì)組學研究的認知，以及分子診斷和臨床醫(yī)學領域的應用。
滬公網(wǎng)安備 31011002002623號
